Pancreatic Adenocarcinoma Panel - Disclosures
|
Panel Member
|
Ajibola Awotiwon MBBS, MSc |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Olca Basturk MD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Al Benson III MD, FACP, FASCO |
|
Grant/Research Support
|
| AbbVie, Inc. | Amgen Inc. | Apexigen | Artemida | Cardiff Oncology | Elevar Therapeutics | Infinity Pharmaceuticals, Inc | ITM Solucin | Janssen Pharmaceutica Products, LP | MedImmune Inc. | Merck & Co., Inc. | Nathan Cummings Foundation | Pfizer Inc. | Rafael Pharmaceuticals | St. Pharma Co. Ltd | SynCore Biotechnology | Tyme Techologies Inc. |
|
Date Completed
|
07/19/2024 |
|
Panel Member
|
Marian Birkeland PhD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Nicole Blankenhorn |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Dana Cardin MD |
|
Grant/Research Support
|
| Elicio Therapeutics | Xbiotech |
|
Date Completed
|
06/24/2024 |
|
Panel Member
|
Elena Gabriela Chiorean MD |
|
Grant/Research Support
|
| AADi | AffiniT | BioMed Valley | Biosplice | Boehringer Ingelheim GmbH | Erasca | Fibrogen | Genentech, Inc. | Gilead Sciences, Inc. | Lonza | National Cancer Institute | Novartis Pharmaceuticals Corporation |
|
Date Completed
|
03/24/2025 |
|
Panel Member
|
Jared Christensen MD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Vincent Chung MD |
|
Grant/Research Support
|
| Merck & Co., Inc. |
|
Date Completed
|
04/16/2025 |
|
Panel Member
|
Brian Czito MD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Marco Del Chiaro MD, PhD |
|
Grant/Research Support
|
| Boston Scientific Corporation | Haemonetics, inc |
|
Date Completed
|
07/29/2024 |
|
Panel Member
|
Mary Dillhoff MD, MS |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Timothy Donahue MD |
|
Equity Interest/Stock Options
|
| Trethera Corporation |
|
Officer, Director or any other fiduciary role
|
| Trethera Corporation |
|
Date Completed
|
06/28/2024 |
|
Panel Member
|
Christos Fountzilas MD, FACP |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Evan Glazer MD, PhD, FACS |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Kristina Gregory MSN, RN |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Evelyn Handel PharmD, BCOP, BCPS |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Laura Hanisch PsyD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Jeffrey Hardacre MD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Kyle Herrmann BSN, RN, OCN |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Erin Hesler |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Anne Holbrook PharmD, BCOP |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Kelsey Klute MD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Andrew Ko MD |
|
Grant/Research Support
|
| Abgenomics (for support of clinical trial; paid directly to my institution) | Apexigen (for support of clinical trial; paid directly to my institution) | Crystal Genomics (for support of clinical trial; paid directly to my institution) | Genentech/Roche (for support of clinical trial; paid directly to my institution) | Novartis (for support of clinical trial; paid directly to my institution) | Revolution Medicines (for support of clinical trial; paid directly to my institution) | Verastem (for support of clinical trial; paid directly to my institution) |
|
Date Completed
|
05/12/2025 |
|
Panel Member
|
John Kunstman MD, MHS |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Kian-Huat Lim MD, PhD |
|
Intellectual Property Rights
|
| Aclaris LLC |
|
Date Completed
|
06/18/2024 |
|
Panel Member
|
Noelle LoConte MD, FASCO |
|
Grant/Research Support
|
| Exact Sciences |
|
Date Completed
|
06/26/2024 |
|
Panel Member
|
Andrew Lowy MD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Mokenge Malafa MD, FACS |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Ashiq Masood MD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Cassadie Moravek BS |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Kristen Morris BSN, RN |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Eric Nakakura MD, PhD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Amol Narang MD |
|
Grant/Research Support
|
| Boston Scientific Corporation | Flavocure | Nanocan |
|
Date Completed
|
07/30/2024 |
|
Panel Member
|
Lorenzo Nardo MD, PhD |
|
Fellowship Support
|
| United Imaging Healthcare - Lorenzo Nardo has is principal investigator of a service agreement with United Imaging Healthcare. UC Davis has a revenue-sharing agreement with United Imaging Healthcare that is based on uEXPLORER sales. Lorenzo Nardo has been the PI of more than 1 service agreements wi | United Imaging Healthcare - Lorenzo Nardo is mentioned in a recurrent gift to support the American Board of Radiology Alternate Pathway at UC Davis |
|
Grant/Research Support
|
| Curium Pharma Healthcare- Lorenzo Nardo is PI of a clinical trial partially supported by Curium Pharma Healthcare | Lantheus - Lorenzo Nardo is PI of a clinical trial partially supported by Lantheus | Lilly - Lorenzo Nardo is Co-I of a clinical trial supported by Lilly; in addition I have signed a honorarium agreement with them, however, I was never paid. | Novartis Pharmaceuticals Corporation | Telix Pharmaceuticals - Lorenzo Nardo is PI of a clinical trial partially supported by Telix | United Imaging Healthcare - Lorenzo Nardo has is principal investigator of a service agreement with United Imaging Healthcare. UC Davis has a revenue-sharing agreement with United Imaging Healthcare that is based on uEXPLORER sales. Lorenzo Nardo has been the PI of more than 1 service agreements wi |
|
Non-royalty Payments
|
| ABR - Lorenzo Nardo served as committee member for the American Board of Radiology - multiple committees. |
|
Salary
|
| Elsivier - Associate editor for Current Problems in Cancer | European Health and Digital Executive Agency- Lorenzo Nardo served a panel reviewer for the European Health and Digital Executive Agency | National Institutes for Health (NIH) - worked in study sections and funded by NIH grant for most of my salary |
|
Date Completed
|
05/12/2025 |
|
Panel Member
|
Jorge Obando MD |
|
Equity Interest/Stock Options
|
| Surgenly LLC |
|
Intellectual Property Rights
|
| Surgenly LLC |
|
Officer, Director or any other fiduciary role
|
| Surgenly LLC |
|
Ownership/Partnership/Principal
|
| Surgenly LLC |
|
Date Completed
|
05/12/2024 |
|
Panel Member
|
Svitlana Ostanina PhD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Patricio Polanco MD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
George Poultsides MD, MS, FACS |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Donna Powell DHSc, CMD, RT(T) |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Swathi Ramakrishnan PhD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Sushanth Reddy MD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Marsha Reyngold MD, PhD |
|
Grant/Research Support
|
| Elekta |
|
Date Completed
|
10/01/2024 |
|
Panel Member
|
Courtney Scaife MD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Ardaman Shergill MD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Mark Truty MD, MS |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Charles Vollmer, Jr. MD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
David Weinberg MD, MSc |
|
Officer, Director or any other fiduciary role
|
| Editor in Chief , Gastroenterology |
|
Date Completed
|
02/09/2025 |
|
Panel Member
|
Robert Wolff MD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Brian Wolpin MD, MPH |
|
Grant/Research Support
|
| Agios, Inc. | Amgen Inc. | AstraZeneca Pharmaceuticals LP | Eli Lilly and Company | Harbinger Health | Novartis Pharmaceuticals Corporation | Revolution Medicines, Inc. |
|
Date Completed
|
12/03/2024 |
